1. Abad M.J., Guerra J.A., Bermejo P., Govil J., Singh V.K., Mishra S.K. Phytochemistry and pharmacology of Tanacetum: recent developments (2008).
2. Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., Fernandes-Alnemri T., Wu J., Monks B.G., Fitzgerald K.A., Hornung V., Latz E. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol., 2009, vol. 183, no. 2, pp. 787—791. doi: 10.4049/jimmunol.0901363
3. Dai Y., Guzman M.L., Chen S., Wang L., Yeung S.K., Pei X.Y., Dent P., Jordan C.T., Grant S. The NF (Nuclear factor)-KB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br. J. Haematol., 2010, vol. 151, no. 1, pp. 70—83. doi: 10.1111/j.1365-2141.2010.08319.x
4. Dammann K., Khare V., Gasche C. Tracing PAKs from GI inflammation to cancer. Gut, 2014, vol. 63, no. 7, pp. 1173—1184. doi: 10.1136/gutjnl-2014-306768
5. Fitzgerald K.N. A few additional treatment possibilities for COVID19 (SARS Cov-2) addressing furin-like cleavage and pyropto-sis (caspase-1 activation of inflammasome NLRP3). URL: https://www.drkarafitzgerald.com/2020/03/25/a-few-additional-treat-ment-possibilities-in-covid19-sars-cov-2-addressing-furin-like-cleavage-and-pyroptosis-caspacin-1-activation-of-inflammasome-nlrp3 (10.09.2020)
6. Juliana C., Fernandes-Alnemri T., Wu J., Datta P., Solorzano L., Yu J.W., Meng R., Quong A.A., Latz E., Scott C.P., Alnemri E.S. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J. Biol. Chem., 2010, vol. 285, no. 13,pp. 9792-9802. doi: 10.1074/jbc.M109.082305
7. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol., 2009, vol. 27, pp. 229-265.
8. Maruta H., He H. A mini-review for COVID-19 issue (2020). URL: http://apitherapy.com/wp-content/uploads/2020/06/Propolis-melatonin-artemisinin-and-other-substances-as-PAK1-blocking-Therapy-of-Pandemic-Coronaviral-Infection-2020-Australia.pdf (20.08.2020)
9. Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med., 2020, vol. 46, no. 5, pp. 846-848. doi: 10.1007/s00134-020-05991-x
10. Smolinski A.T., Pestka J.J. Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver. J. Inflamm., 2005, no. 2: 6. doi: 10.1186/1476-9255-2-6
11. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lancet, 2020, vol. 395, no. 10223, pp. 470-473. doi: 10.1016/S0140-6736(20)30185-9
